Heart failure & cardiomyopathiesMeta-analysis
Risk Stratification in Nonischemic Dilated Cardiomyopathy Using Cardiac Magnetic Resonance (CMR) Imaging
- Systematic review and meta-analysis of nonrandomized diagnostic studies
- random-effects
Authors' conclusion
The presence and extent of LGE were associated with various adverse clinical outcomes, whereas LVEF was not significantly associated with mortality and arrhythmic end points in NIDCM.
Study context
- Population
- Patients with nonischemic dilated cardiomyopathy (NIDCM)
- Participants
- 29,687 patients · 103 studies
- Comparison
- CMR-derived measurements and clinical outcomes
- Outcome
- All-cause mortality, CV mortality, arrhythmic events, HF events and MACE
Pooled result
As reported in the abstract
- Late gadolinium enhancement (LGE) presence: all-cause mortality, HR
- 1.81 (1.60-2.04); P < .001 (95% CI)
- LGE extent (per 1%): all-cause mortality, HR
- 1.07 (1.02-1.12); P = .02 (95% CI)
- LGE presence: CV mortality, HR
- 2.43 (2.13-2.78); P < .001 (95% CI)
- LGE extent (per 1%): CV mortality, HR
- 1.15 (1.07-1.24); P = .01 (95% CI)
- LGE presence: arrhythmic events, HR
- 2.69 (2.20-3.30); P < .001 (95% CI)
- LGE extent (per 1%): arrhythmic events, HR
- 1.07 (1.03-1.12); P = .004 (95% CI)
- LGE presence: HF events, HR
- 1.98 (1.73-2.27); P < .001 (95% CI)
- LGE extent (per 1%): HF events, HR
- 1.06 (1.01-1.10); P = .02 (95% CI)
- Left ventricular ejection fraction (LVEF) (per 1%): all-cause mortality, HR
- 0.99 (0.97-1.02); P = .47 (95% CI)
- LVEF (per 1%): CV mortality, HR
- 0.97 (0.94-1.00); P = .05 (95% CI)
- LVEF (per 1%): arrhythmic outcomes, HR
- 0.99 (0.97-1.01); P = .34 (95% CI)
- LVEF (per 1%): HF events, HR
- 0.97 (0.95-0.98); P = .002 (95% CI)
- LVEF (per 1%): Major adverse cardiac events (MACE), HR
- 0.98 (0.96-0.99); P < .001 (95% CI)
- Native T1 (per 10 ms): arrhythmic events, HR
- 1.07 (1.01-1.14); P = .04 (95% CI)
- Native T1 (per 10 ms): MACE, HR
- 1.06 (1.01-1.11); P = .03 (95% CI)
- Global longitudinal strain (GLS) (per 1%): HF events, HR
- 1.06 (0.95-1.18); P = .15 (95% CI)
- GLS (per 1%): MACE, HR
- 1.03 (0.94-1.14); P = .43 (95% CI)
Original publication
Risk Stratification in Nonischemic Dilated Cardiomyopathy Using CMR Imaging. JAMA. Published 19 September 2024. doi:10.1001/jama.2024.13946
Summarised from the published abstract; every number is checked against it